🔎 Trials Near Me

Hjem › Osteosarkom › Massachusetts

Osteosarkom kliniske forsøg i Massachusetts

9 studier for Osteosarkom søger deltagere på steder i Massachusetts.

Byer i Massachusetts

Officiel studietekst (engelsk)

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  • Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 12 til 39 · Alle køn · Opdateret 29. sep. 2026 · NCT04616560

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
RekruttererFase 3
Op til 50 år · Alle køn · Opdateret 25. aug. 2026 · NCT05235165

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
12 Months – 30 Years · Alle køn · Opdateret 25. aug. 2026 · NCT04851119

SPEARHEAD-3 Pediatric Study

  • Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 2 til 21 · Alle køn · Opdateret 11. aug. 2026 · NCT05642455

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

  • Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Op til 30 år · Alle køn · Opdateret 3. aug. 2026 · NCT06239272

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Dana-Farber Cancer Institute, Boston
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 18. maj 2026 · NCT01790152

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

  • Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 1. maj 2026 · NCT07357519

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

  • Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 12 og opefter · Alle køn · Opdateret 17. apr. 2026 · NCT05019703

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

  • Boston Children's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
  • Brigham and Women's Hospital, Boston
RekruttererFase 1/2
Alder 12 til 49 · Alle køn · Opdateret 19. feb. 2026 · NCT06709495

Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.